Literature DB >> 26346637

Dysfunctional Striatal Systems in Treatment-Resistant Schizophrenia.

Thomas P White1,2, Rebekah Wigton1,3,4, Dan W Joyce1, Tracy Collier1, Alex Fornito5, Sukhwinder S Shergill1.   

Abstract

The prevalence of treatment-resistant schizophrenia points to a discrete illness subtype, but to date its pathophysiologic characteristics are undetermined. Information transfer from ventral to dorsal striatum depends on both striato-cortico-striatal and striato-nigro-striatal subcircuits, yet although the functional integrity of the former appears to track improvement of positive symptoms of schizophrenia, the latter have received little experimental attention in relation to the illness. Here, in a sample of individuals with schizophrenia stratified by treatment resistance and matched controls, functional pathways involving four foci along the striatal axis were assessed to test the hypothesis that treatment-resistant and non-refractory patients would exhibit contrasting patterns of resting striatal connectivity. Compared with non-refractory patients, treatment-resistant individuals exhibited reduced connectivity between ventral striatum and substantia nigra. Furthermore, disturbance to corticostriatal connectivity was more pervasive in treatment-resistant individuals. The occurrence of a more distributed pattern of abnormality may contribute to the failure of medication to treat symptoms in these individuals. This work strongly supports the notion of pathophysiologic divergence between individuals with schizophrenia classified by treatment-resistance criteria.

Entities:  

Mesh:

Year:  2015        PMID: 26346637      PMCID: PMC4793111          DOI: 10.1038/npp.2015.277

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  58 in total

Review 1.  The reward circuit: linking primate anatomy and human imaging.

Authors:  Suzanne N Haber; Brian Knutson
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

2.  Dysconnectivity of the inferior frontal gyrus: implications for an impaired self-other distinction in patients with schizophrenia.

Authors:  Bianca Backasch; Jens Sommer; Farahnaz Klöhn-Saghatolislam; Matthias J Müller; Tilo T J Kircher; Dirk T Leube
Journal:  Psychiatry Res       Date:  2014-05-28       Impact factor: 3.222

3.  The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry.

Authors:  Thomas R Insel
Journal:  Am J Psychiatry       Date:  2014-04       Impact factor: 18.112

4.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

Authors:  I Creese; D R Burt; S H Snyder
Journal:  Science       Date:  1976-04-30       Impact factor: 47.728

5.  Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

Authors:  B Moghaddam; B Adams; A Verma; D Daly
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

6.  Increased synaptic dopamine function in associative regions of the striatum in schizophrenia.

Authors:  Lawrence S Kegeles; Anissa Abi-Dargham; W Gordon Frankle; Roberto Gil; Thomas B Cooper; Mark Slifstein; Dah-Ren Hwang; Yiyun Huang; Suzanne N Haber; Marc Laruelle
Journal:  Arch Gen Psychiatry       Date:  2010-03

7.  Functional connectivity and brain networks in schizophrenia.

Authors:  Mary-Ellen Lynall; Danielle S Bassett; Robert Kerwin; Peter J McKenna; Manfred Kitzbichler; Ulrich Muller; Ed Bullmore
Journal:  J Neurosci       Date:  2010-07-14       Impact factor: 6.167

8.  Dissociable roles of ventral and dorsal striatum in instrumental conditioning.

Authors:  John O'Doherty; Peter Dayan; Johannes Schultz; Ralf Deichmann; Karl Friston; Raymond J Dolan
Journal:  Science       Date:  2004-04-16       Impact factor: 47.728

9.  Clozapine-resistant psychosis, smoking, and caffeine: managing the neglected effects of substances that our patients consume every day.

Authors:  Luiz Dratcu; Alistair Grandison; Gavin McKay; Adekunle Bamidele; Vinodini Vasudevan
Journal:  Am J Ther       Date:  2007 May-Jun       Impact factor: 2.688

10.  Dysregulated but not decreased salience network activity in schizophrenia.

Authors:  Thomas P White; James Gilleen; Sukhwinder S Shergill
Journal:  Front Hum Neurosci       Date:  2013-03-07       Impact factor: 3.169

View more
  19 in total

Review 1.  Functional connectivity as a means to delineate differences between treatment-resistant and treatment-responsive schizophrenia.

Authors:  Sara Paul; Nathan Sharfman
Journal:  J Neurophysiol       Date:  2016-01-13       Impact factor: 2.714

2.  Aberrant Frontostriatal Connectivity in Negative Symptoms of Schizophrenia.

Authors:  Dinesh K Shukla; Joshua John Chiappelli; Hemalatha Sampath; Peter Kochunov; Stephanie M Hare; Krista Wisner; Laura M Rowland; L Elliot Hong
Journal:  Schizophr Bull       Date:  2019-09-11       Impact factor: 9.306

3.  Ultrastructural evidence for glutamatergic dysregulation in schizophrenia.

Authors:  Rosalinda C Roberts; Lesley A McCollum; Kirsten E Schoonover; Samuel J Mabry; Joy K Roche; Adrienne C Lahti
Journal:  Schizophr Res       Date:  2020-01-31       Impact factor: 4.939

4.  Neural substrate of unrelenting negative symptoms in schizophrenia: a longitudinal resting-state fMRI study.

Authors:  Mingli Li; Wei Deng; Tushar Das; Yinfei Li; Liansheng Zhao; Xiaohong Ma; Yingcheng Wang; Hua Yu; Xiaojing Li; Ya-Jing Meng; Qiang Wang; Lena Palaniyappan; Tao Li
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-11-11       Impact factor: 5.270

5.  White Matter in Schizophrenia Treatment Resistance.

Authors:  Peter Kochunov; Junchao Huang; Song Chen; Yanli Li; Shuping Tan; Fengmei Fan; Wei Feng; Yunhui Wang; Laura M Rowland; Anya Savransky; Xiaoming Du; Joshua Chiappelli; Shuo Chen; Neda Jahanshad; Paul M Thompson; Meghann C Ryan; Bhim Adhikari; Hemalatha Sampath; Yimin Cui; Zhiren Wang; Fude Yang; Yunlong Tan; L Elliot Hong
Journal:  Am J Psychiatry       Date:  2019-07-29       Impact factor: 18.112

6.  A neuroimaging biomarker for striatal dysfunction in schizophrenia.

Authors:  Ang Li; Andrew Zalesky; Weihua Yue; Oliver Howes; Hao Yan; Yong Liu; Lingzhong Fan; Kirstie J Whitaker; Kaibin Xu; Guangxiang Rao; Jin Li; Shu Liu; Meng Wang; Yuqing Sun; Ming Song; Peng Li; Jun Chen; Yunchun Chen; Huaning Wang; Wenming Liu; Zhigang Li; Yongfeng Yang; Hua Guo; Ping Wan; Luxian Lv; Lin Lu; Jun Yan; Yuqing Song; Huiling Wang; Hongxing Zhang; Huawang Wu; Yuping Ning; Yuhui Du; Yuqi Cheng; Jian Xu; Xiufeng Xu; Dai Zhang; Xiaoqun Wang; Tianzi Jiang; Bing Liu
Journal:  Nat Med       Date:  2020-03-23       Impact factor: 53.440

7.  Abnormal Resting-State Connectivity in a Substantia Nigra-Related Striato-Thalamo-Cortical Network in a Large Sample of First-Episode Drug-Naïve Patients With Schizophrenia.

Authors:  Matteo Martino; Paola Magioncalda; Hua Yu; Xiaojing Li; Qiang Wang; Yajing Meng; Wei Deng; Yinfei Li; Mingli Li; Xiaohong Ma; Timothy Lane; Niall W Duncan; Georg Northoff; Tao Li
Journal:  Schizophr Bull       Date:  2018-02-15       Impact factor: 9.306

8.  Functional Dysconnectivity in Ventral Striatocortical Systems in 22q11.2 Deletion Syndrome.

Authors:  Ángeles Tepper; Analía Cuiza; Luz María Alliende; Carlos Mena; Juan Pablo Ramirez-Mahaluf; Barbara Iruretagoyena; Claudia Ornstein; Rosemarie Fritsch; Ruben Nachar; Alfonso González-Valderrama; Juan Undurraga; Juan Pablo Cruz; Cristian Tejos; Alex Fornito; Gabriela Repetto; Nicolas Crossley
Journal:  Schizophr Bull       Date:  2022-03-01       Impact factor: 9.306

9.  Motivational deficits in schizophrenia relate to abnormalities in cortical learning rate signals.

Authors:  D Hernaus; Z Xu; E C Brown; R Ruiz; M J Frank; J M Gold; J A Waltz
Journal:  Cogn Affect Behav Neurosci       Date:  2018-12       Impact factor: 3.282

10.  Functional Striatal Abnormalities: A Distinct Brain Signature of Schizophrenia.

Authors:  Sugai Liang; Tao Li
Journal:  Neurosci Bull       Date:  2020-10-23       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.